Paul Markham, investment director and global equities head at GAM Investments, discusses the relief rally in US stocks and bonds is extending for a second session after fears of a protracted US-Israeli war against Iran triggered seismic moves in oil markets. "The idea that this will be a sustained rally from here, for me is quite difficult to believe," Markham tells Bloomberg Television.
US President Donald Trump has predicted the war with Iran would resolve 'very soon.' Trump says he would waive oil-related sanctions and have the US Navy escort tankers through the Strait of Hormuz. Stuart Livingstone-Wallace, Bloomberg's Executive Editor for Middle East, North Africa and Russia, and Sam Dagher, Bloomberg's Senior Middle East Reporter have the latest.
Volkswagen CFO Arno Antlitz comments on earnings, cost savings and the outlook for growth in China. He speaks to Bloomberg's Oliver Crook after the firm, Europe's largest automaker, forecast an operating return in a range of 4% to 5.5% this year as higher raw material costs, intense competition and geopolitical tensions combine for a challenging outlook.
In times of uncertainty, we often look for something solid to hold onto. Lately, it seems the world’s investors have decided that “something solid” is, quite literally, gold.
The metal’s soaring price is more than just a market trend; it's a global barometer of anxiety.
When faith in currencies, governments, and traditional financial systems begins to waver, we see a familiar flight to the perceived safety of this timeless asset.
Well, pull out the party hats and dust off the stock tickers.
Lithium, the commodity that investors and analysts had all but left for dead in the great market purge of 2023-2024, is back.
The stock market has long treated Tesla (NASDAQ:TSLA) less as a traditional automaker and more as a futuristic technology cult, with its valuation soaring on the gravitational pull of its CEO, Elon Musk.
This persistent "Musk Premium" has burned countless short-sellers.
Bitcoin has vaporised more than US$800 billion in its latest crash and sucked US$1 trillion out of the broader crypto market.
With nearly US$2 trillion in market value and rising allocations from Wall Street firms, ETFs, pension funds, and insurers, Bitcoin is increasingly woven into traditional finance.
Global energy markets are reeling as oil tracks toward its most significant weekly gain in four years, fuelled by escalating conflict in the Middle East.
Global oil prices held steady on March 3 as energy markets braced for an intensification of conflict in the Middle East.
U.S. Customs and Border Protection (CBP) will officially stop collecting billions in trade duties at 12:01 a.m. EST on Tuesday, following a landmark Supreme Court ruling that declared President Donald Trump’s use of emergency powers to levy tariffs illegal.
Bloomberg Opinion Columnist Javier Blas says using the East-West oil pipeline that runs across the Arabian Peninsula, and another pipeline owned by the United Arab Emirates, can help get oil to market by avoiding the Strait of Hormuz. He says doing so, could help slow down rising oil and gasoline prices. He speaks on Bloomberg Open Interest.
Hims & Hers Health (NYSE:HIMS) shares surged as much as 52% in early trading Monday after the telehealth leader announced a surprising end to its legal battle with Novo Nordisk.
Korn Ferry (NYSE:KFY) reported a strong third quarter for fiscal 2026, with fee revenue reaching $717.4 million as the global consulting firm successfully leveraged high-growth digital services and long-term contracts to offset broader economic shifts.
HUTCHMED initiated a full market recall of the oncology drug Tazverik across Greater China on Monday, following a global withdrawal by partner Ipsen due to emerging safety data linking the therapy to secondary blood cancers.
Hewlett Packard Enterprise (NYSE:HPE) reported third-quarter financial results that showcased a significant acceleration in top-line growth, fueled by robust demand for its "as-a-service" offerings and high-performance computing.
Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.